195 related articles for article (PubMed ID: 33842926)
1. Addressing cervical cancer screening disparities through advances in artificial intelligence and nanotechnologies for cellular profiling.
Yang Z; Francisco J; Reese AS; Spriggs DR; Im H; Castro CM
Biophys Rev (Melville); 2021 Mar; 2(1):011303. PubMed ID: 33842926
[TBL] [Abstract][Full Text] [Related]
2. Screening for cancer in low- and middle-income countries.
Sankaranarayanan R
Ann Glob Health; 2014; 80(5):412-7. PubMed ID: 25512156
[TBL] [Abstract][Full Text] [Related]
3. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
Della Palma P; Moresco L; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
[TBL] [Abstract][Full Text] [Related]
4. Current Status and Future Perspectives of Molecular Prevention Strategies for Cervical Cancers.
Krishnamurthy A; Ramshankar V
Indian J Surg Oncol; 2020 Dec; 11(4):752-761. PubMed ID: 33299288
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential.
Sahasrabuddhe VV; Parham GP; Mwanahamuntu MH; Vermund SH
Cancer Prev Res (Phila); 2012 Jan; 5(1):11-7. PubMed ID: 22158053
[TBL] [Abstract][Full Text] [Related]
6. Leveraging COVID-era innovation for cervical cancer screening: Clinician awareness and attitudes toward self-sampling and rapid testing for HPV detection.
Rodriguez NM; Brennan LP; Claure L; Balian LN; Champion VL; Forman MR
PLoS One; 2023; 18(3):e0282853. PubMed ID: 36893182
[TBL] [Abstract][Full Text] [Related]
7. Human Papilloma Virus self-sampling performance in low- and middle-income countries.
Kamath Mulki A; Withers M
BMC Womens Health; 2021 Jan; 21(1):12. PubMed ID: 33407355
[TBL] [Abstract][Full Text] [Related]
8. Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges.
Pimple SA; Mishra GA
Minerva Ginecol; 2019 Oct; 71(5):365-371. PubMed ID: 31698891
[TBL] [Abstract][Full Text] [Related]
9. The early detection of cervical cancer. The current and changing landscape of cervical disease detection.
Shiraz A; Crawford R; Egawa N; Griffin H; Doorbar J
Cytopathology; 2020 Jul; 31(4):258-270. PubMed ID: 32301535
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
11. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
12. Researchers should no longer delay implementation of Pap screening in low and middle income countries pending research into novel screening approaches.
Suba EJ
Infect Agent Cancer; 2024 Apr; 19(1):18. PubMed ID: 38671517
[TBL] [Abstract][Full Text] [Related]
13. Implementation of a centralized HPV-based cervical cancer screening programme in Tuscany: First round results and comparison with the foregoing Pap-based screening programme.
Carozzi F; Burroni E; Confortini M; Pompeo G; Bisanzi S; Cellai F; Paganini I; Mantellini P; Iossa A; Lelli L; Di Pierro C; Matucci M; Cannistrà S; Rosati R; Mongia A; Visioli CB; Gorini G; Sani C; The Tuscany Hpv-Based Screening Working Group
J Med Screen; 2022 Jun; 29(2):110-122. PubMed ID: 35038279
[TBL] [Abstract][Full Text] [Related]
14. Cervical Cancer Screening Preferences Among Trans-Masculine Individuals: Patient-Collected Human Papillomavirus Vaginal Swabs Versus Provider-Administered Pap Tests.
McDowell M; Pardee DJ; Peitzmeier S; Reisner SL; Agénor M; Alizaga N; Bernstein I; Potter J
LGBT Health; 2017 Aug; 4(4):252-259. PubMed ID: 28665783
[TBL] [Abstract][Full Text] [Related]
15. Anal dysplasia screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(4):1-43. PubMed ID: 23074504
[TBL] [Abstract][Full Text] [Related]
16. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
17. Study protocol for a two-site clinical trial to validate a smartphone-based artificial intelligence classifier identifying cervical precancer and cancer in HPV-positive women in Cameroon.
Baleydier I; Vassilakos P; Viñals R; Wisniak A; Kenfack B; Tsuala Fouogue J; Enownchong Enow Orock G; Lemoupa Makajio S; Foguem Tincho E; Undurraga M; Cattin M; Makohliso S; Schönenberger K; Gervaix A; Thiran JP; Petignat P
PLoS One; 2021; 16(12):e0260776. PubMed ID: 34914727
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for advances in cervical screening.
Doorbar J; Cubie H
Mol Diagn; 2005; 9(3):129-42. PubMed ID: 16271014
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
